Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2628 participants.
Also called NCT07430956
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 2,628 participants
- Sponsor
- Registry
-
NCT07430956 -
2025-521618-25-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Canada
- Registry status
- Recruiting
Technical summary
Registry record NCT07430956. Randomized; quadruple masking; primary purpose prevention. Start 2026-04-03 (actual); primary completion 2029-03-28 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
- Acronym
- ROXI-INCLINE
- Condition
- Atrial Fibrillation (AF)
- Intervention (Drug)
- REGN7508
- Intervention (Drug)
- REGN9933
- Intervention (Drug)
- Placebo
- Lead sponsor
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct07430956- Content hash
b07965521e743ecb85713eb566ab5ae68b16e0184e12b0eb30c712a36cd049ee